Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Depreciation and Depletion: 2019-2025

Historic Depreciation and Depletion for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $300,000.

  • Fulcrum Therapeutics' Depreciation and Depletion fell 25.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 23.56%. This contributed to the annual value of $1.6 million for FY2024, which is 27.27% down from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Depreciation and Depletion is $300,000, which was down 0.00% from $300,000 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Depreciation and Depletion registered a high of $700,000 during Q2 2021, and its lowest value of $300,000 during Q2 2025.
  • In the last 3 years, Fulcrum Therapeutics' Depreciation and Depletion had a median value of $400,000 in 2025 and averaged $443,273.
  • Per our database at Business Quant, Fulcrum Therapeutics' Depreciation and Depletion climbed by 20.00% in 2021 and then plummeted by 33.33% in 2024.
  • Fulcrum Therapeutics' Depreciation and Depletion (Quarterly) stood at $615,000 in 2021, then decreased by 3.90% to $591,000 in 2022, then declined by 15.40% to $500,000 in 2023, then decreased by 24.80% to $376,000 in 2024, then decreased by 25.00% to $300,000 in 2025.
  • Its Depreciation and Depletion stands at $300,000 for Q3 2025, versus $300,000 for Q2 2025 and $400,000 for Q1 2025.